NCT01099683View on ClinicalTrials.gov

Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in Elderly Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Fecal Incontinence
Interventions
DRUG

NRL001

Single rectal administration of 2 mg NRL001 in a 2 g suppository

DRUG

Placebo

All subjects will receive rectal suppository containing placebo

Trial Locations (1)

BT2 7BA

Bio-Kinetic Europe Ltd, Belfast

Sponsors

Lead Sponsor

Norgine
All Listed Sponsors
lead

Norgine

INDUSTRY